This week in drug discovery (7-11 July)
News round-up for 7-11 July by DDW Senior Digital Content Editor Diana Turner.
This week our news highlights focus on the drug discovery in the European Union, including some new regulatory approvals from the European Commission, advancements from Netherlands-based argenx, a new PhD programme in Estonia, and Switzerland’s evolution as a deep tech leader.
The top stories:
EU-Funded PhD programme to advance sustainable drug discovery
Optibrium has partnered with Tallinn University of Technology (TalTech) to co-supervise an EU-funded PhD position as part of the INNOCHEMBIO programme.
argenx advances ARGX-119 in congenital myasthenic syndromes
argenx has announced it will advance ARGX-119, a first-in-class agonist antibody to muscle-specific kinase (MuSK), to a registrational study in patients with congenital myasthenic syndromes (CMS).
Switzerland becomes a global leader in Deep Tech
A new report has spotlighted how Switzerland has become one of the world’s most advanced Deep Tech ecosystems, led in part by the rise in the number of techbio start-ups in the country.
EU-approved bladder cancer therapy reduces death risk by 25%
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment.
EC approves Vertex’s CFTR modulator for cystic fibrosis
The European Commission (EC) has granted approval for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages six years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
